He, Jiaping

Updated results of a phase I, open-label study of BCMA/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM).

Du, J., Fu, W.-J., Jiang, H., Dong, B., Gao, L., Liu, L., Ge, J., He, A., Li, L., Lu, J., et al. (2023) · Journal of Clinical Oncology

CAR-T cell therapy researchMultiple Myeloma Research and Treatments

Cited by 35

A feasibility and safety study of a new CD19-directed fast CAR-T therapy for refractory and relapsed B cell acute lymphoblastic leukemia

Yang, J., He, J., Zhang, X., Wang, Z., Zhang, Y., Cai, S., Sun, Z., Ye, X., He, Y., Shen, L., et al. (2019) · Blood

CAR-T cell therapy researchAcute Lymphoblastic Leukemia research

Cited by 20

CD19-directed fast CART therapy for relapsed/refractory acute lymphoblastic leukemia: from bench to bedside

Zhang, C., He, J., Liu, L., Wang, J., Wang, S., Liu, L., Gao, L., Gao, L., Liu, Y., Kong, P., et al. (2019) · Blood

CAR-T cell therapy researchAcute Lymphoblastic Leukemia research

Cited by 17